Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold

2 weeks from now

Jan 6, 2025  · JPMorgan Chase & Co. decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 7.2% in the 3rd quarter, according to the company in its …

marketbeat.com

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

2 weeks from now

1 day ago  · Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($1.38) earnings per …

marketbeat.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold By …

2 weeks from now

Jan 6, 2025  · JPMorgan Chase & Co. reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 7.2% during the 3rd quarter, according to its most …

defenseworld.net

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold By …

2 weeks from now

Dec 5, 2024  · Finally, nVerses Capital LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $96,000. 62.61% of the stock is owned by …

etfdailynews.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO …

2 weeks from now

Jan 7, 2025  · On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a …

etfdailynews.com

Arrowhead Stock Price Today | NASDAQ: ARWR Live - Investing.com

2 weeks from now

Christopher Anzalone, the Chief Executive Officer of Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), recently sold shares worth approximately $219,456. The transaction, …

investing.com

Arrowhead Pharmaceuticals Nabs Massive Sarepta Licensing Deal; …

2 weeks from now

Nov 26, 2024  · Arrowhead shares rocketed 12% to close at 21.05 and ARWR stock leapfrogged its 50-day line, according to MarketSurge. Sarepta stock jumped too, 13.8% to 130.50, putting …

investors.com

Arrowhead Pharmaceuticals (ARWR) P/E Ratio - Public.com

2 weeks from now

The P/E ratio for Arrowhead Pharmaceuticals (ARWR) is -3.78 as of Jan 13, 2025.This represents a decrease of-40.75% compared to its 12-month average P/E ratio of-6.38.A higher P/E ratio …

public.com

Read This Before Buying Arrowhead Pharmaceuticals, Inc ... - Nasdaq

2 weeks from now

Jun 13, 2021  · Read This Before Buying Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares June 13, 2021 — 03:37 am EDT. ... Curt Bradshaw, sold US$1.1m worth of shares at …

nasdaq.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO ... - ETF …

2 weeks from now

Jan 8, 2025  · Shares of NASDAQ ARWR opened at $19.67 on Wednesday. The firm’s 50 day moving average price is $21.03 and its 200 day moving average price is $22.56. The company …

etfdailynews.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 2.5

2 weeks from now

Jan 6, 2025  · Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report)'s stock price fell 2.5% on Monday . The company traded as low as $19.27 and last traded at $19.30. 89,235 …

marketbeat.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 3.2

2 weeks from now

Jan 8, 2025  · Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) shares rose 3.2% during trading on Wednesday . The stock traded as high as $20.34 and last traded at …

marketbeat.com

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025  · Shares of Sarepta Therapeutics SRPT have risen 23% in the past year, significantly outperforming the industry’s 15.7% decline, as shown in the chart below. During this …

nasdaq.com

Arrowhead Pharmaceuticals (ARWR) Earnings Date And Reports 2025

2 weeks from now

1 day ago  · Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$599.49 million. ARWR has generated -$5.02 earnings per share over the last four quarters. …

marketbeat.com